| An orally administered oxazolidinone antibacterial agent is being developed by Shanghai MicuRx Pharmaceutical Co., Ltd. for the treatment of MDR Gram-positive bacterial infections |
| Received its first approval on 1 June 2021 in China |
| Approved for use in cSSTI |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.